AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 52 min read$MBRX

PICKER DONALD H purchased 173,333 shares of MBRX

PICKER DONALD H (Chief Science Officer) purchased 173,333 shares of Moleculin Biotech, Inc. (MBRX) on 2026-08-03.

Original reporting
SEC EDGAR · PICKER DONALD H
Published Aug 5, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 3:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MBRX
Bullish
low confidence
Mentioned
$MBRX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MBRXBullishLow
01

Why it matters

The newest fact is the CSO’s open-market purchase of 173,333 shares (dated 2026-08-03) reported on 2026-08-05.

02

Market read

Traders may treat the filing as a small sentiment input, but it does not provide new clinical, regulatory, or financial information.

03

What to watch

No 10b5-1 plan and no disclosed transaction price/value, so the signal strength is weaker than a large, priced buy tied to a clear thesis.

Relevance 4/10Novelty 5/10Timing: filed 2026-08-05, transaction dated 2026-08-03

Background

This is an SEC Form 4 insider transaction disclosure for Moleculin Biotech, Inc.

Company-level read

Ticker impact

$MBRXBullishLow confidence
Context

Form 4 shows Moleculin Biotech CSO Picker Donald H bought 173,333 shares on 2026-08-03, increasing direct holdings to 174,086.

Expected impact

Low to modest positive bias for sentiment; limited impact on fundamentals unless followed by additional disclosures.

Evidence & confidence

The filing is a primary-source insider transaction, but the price is not disclosed and there is no accompanying operational or financial update.

Market effects

Sector

Minimal. Single insider purchase in a biotech does not reset sector expectations.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider buys can be routine diversification or planned liquidity needs, especially without disclosed price or context.

Key entities

  • issuer
    Moleculin Biotech, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Picker Donald H

    Chief Science Officer who executed the open-market purchase.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MBRX insider trading history →

Related articles

SEP 29
$MBRXLow

Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout

Moleculin Biotech, Inc. (MBRX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout – Rapid completion of Part A enrollment underscores strong operational execution and investigator engagement in relapsed or refracto

SEC EDGAR 8-K2 min
SEP 28
$MBRXMedAI 8/10

Moleculin Advances Annamycin Following Peer-Reviewed Cardiac Safety Data

Moleculin Biotech (MBRX) published a peer-reviewed analysis in Frontiers in Cardiovascular Medicine, showing no cardiotoxicity in 90 patients treated with Annamycin across five trials. The study, evaluated by Cleveland Clinic, found no significant changes in left ventricular ejection fraction (LVEF) and no treatment-related cardiotoxicity. Annamycin is being evaluated in the MIRACLE trial for relapsed or refractory AML.

rttnews.com2 min
SEP 28
$MBRXMedAI 8/10

Moleculin Reports Cardiac Safety Findings For Annamycin In Pooled Analysis

Moleculin Biotech (MBRX) published cardiac safety findings for Annamycin, showing no evidence of cardiotoxicity in 90 patients across five trials. Mean LVEF remained stable, and no relationship was found between cumulative Annamycin exposure and LVEF changes. The analysis supports continued clinical evaluation of Annamycin, which is being studied in the MIRACLE trial for relapsed or refractory AML. MBRX stock closed at $0.60, up 6.12%, and is currently down 1.26% in pre-market trading.

rttnews.com2 min
SEP 28
$MBRXMedAI 8/10

Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine

Moleculin Biotech, Inc. (MBRX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine – Pooled analysis of five clinical trials found no clinical or subclinical evidence of cardiotoxicity at cumulative doses exceeding tradition

SEC EDGAR 8-K2 min
SEP 25
$MBRXMedAI 8/10

Moleculin Biotech, Inc. (MBRX): Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR

Moleculin Biotech, Inc. (MBRX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Annamycin Turns “ Cold ” Pancreatic Tumors “ Hot ” in New Preclinical Data Presented at AACR Data presented at the AACR Conference on Pancreatic Cancer indicate Annamycin ’ s antitumor activity is partially mediated by CD8+ T cells, supporting a potential immune-medi

SEC EDGAR 8-K1 min